| Project/Area Number |
08671466
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | YOKOHAMA CITY UNIVERSITY |
|---|
Principal Investigator |
AKAHASHI Masazumi Yokohama City University, Dept. of Medicine, Assisitant Prof., 医学部・附属病院, 助手 (10188055)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
ISHIKAWA Takashi Yokohama City University, Dept. of Medicine, Assistant Prof., 医学部, 助手 (80275049)
YAMAOKA Hiroyuki Yokohama City University, Dept. of Medicine, Associate Prof., 医学部, 講師 (90230317)
|
|---|
| Project Period (FY) |
1996 – 1998
|
| Project Status |
Completed (Fiscal Year 1998)
|
| Budget Amount *help |
¥2,200,000 (Direct Cost: ¥2,200,000)
Fiscal Year 1998: ¥100,000 (Direct Cost: ¥100,000)
Fiscal Year 1997: ¥200,000 (Direct Cost: ¥200,000)
Fiscal Year 1996: ¥1,900,000 (Direct Cost: ¥1,900,000)
|
|---|
| Keywords | ras / monoclonal antibody / T-cell / pancreatic cancer / colon cancer / B-cell / ras癌遺伝子 / テロメラーゼ |
|---|
| Research Abstract |
Immune responses to ras oncogenic products were studied in pancreatic and colon cancer patients. Positive rates for serum anti-ras antibody were significantly higher in patients with pancreatic cancer (8O%, 4/5, p<O.05) and colon cancer (40%, 51/150, p<O.Ol) as compared to normal donors (55, 2/40). The anti-ras antibodies recognized normal or mutated segments of p21ras protein, and 73% of colon cancer patients had antibodies to the carboxyl terminus of p2lras protein. T lymphocyte detection rates for specific ras peptides were significantly higher in patients with pancreatic cancer (40%, 6/15, p<O.Ol) and colon cancer (24%, 6/25, p<O.Ol) as compared to normal donors (0%, 0/20). We attempted to elicit cytotoxic T lymphocyte for ras peptides, and found the CD4+ CTL specific for the normal carboxyl terminus of the p2lras protein could be elicited from peripheral blood lymphocytes from one of the three patients with pancreatic cancer. The results suggest that diagnosis of the existence, based on serum antibodies to ras oncogenic proteins, and immunotherapy with CTL specific for ras oncogenic proteins are promising future medical treatments for pancreatic and colon cancer patients.
|
